Why the study?
Do different commercially available factor Xa reagents perform similarly in a fluorogenic anti-FXa assay for monitoring unfractionated heparin?
Do different commercially available factor Xa reagents perform similarly in a fluorogenic anti-FXa assay for monitoring unfractionated heparin?
Four commercially available factor Xa reagents showed similar performance in a fluorogenic anti-FXa assay, supporting the potential for standardization of coagulation assays in clinical settings.
May support anti-FXa assay standardization; leaves open human validation for heparin monitoring.
Four commercially available factor Xa (FXa) reagents were evaluated in a fluorogenic anti-FXa assay. The four reagents - of which three were of human origin and the fourth was bovine - were compared in terms of the resulting assay dynamic ranges, lag times, coefficient of variation and R2 values, as well as their sensitivity to unfractionated heparin within the therapeutic range of 0-1.2 U/ml. Similar performance of reagents in the fluorogenic anti-FXa assay was observed independent of the source of the reagent or its physical state, which may assist in the standardization of coagulation assays in clinical settings.
No takes yet. Share an insight, caveat, or question.
Castro-López et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: